Denecimig not checked
Novo Nordisk · NNC0365-3769 · Mim8
FollowEvery change as it happens, and a Monday email
Trials
2 active
7 in total · 2 in the EU
What this is
- How it works
- An antibody built to latch onto two or more targets at once.-mig: multi-specific immunoglobulins WHO name stem
- How it’s given
- “Participants in arm 1 will administer Mim8 using an enhanced cartridge and switch to the DV3407 pen-injector once it is approved. Participants in arm 2 and 3 will use the DV3407 pen injector.”In the company’s words, NCT05685238 on ClinicalTrials.gov
- Tested for
- Haemophilia A (2 trials), Haemophilia A With Inhibitors
- Main trialPhase 3
- “This study is looking at how Mim8 works in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used to avoid bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). The study will last for up to 5.5 years. The duration of the study depends on when the participant enrolled in this study. The study will end if Mim8 is approved and marketed in participant's country during the study, or the study will end in June 2028, whichever comes first. Participants will get up to 262 injections; the…”In the company’s words, NCT05685238 on ClinicalTrials.gov
- Other names
- NNC0365-3769 · Mim8
Other drugs for Haemophilia A
- GS1191-0445Gritgen Therapeutics Co., Ltd. · Phase 3
- FRSW107Hangzhou Gensciences Biopharmaceutical Co., Ltd. · Phase 3
- SR604Shanghai RAAS Blood Products Co., Ltd. · Phase 3
- NXT007Roche · Phase 3
- KN057Suzhou Alphamab Co., Ltd. · Phase 3
- MarstacimabPfizer · Phase 3
Coming up2
- 30 Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- 23 Mar 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 30 Jun 2028 | A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A | |
| Phase 3Recruiting | 23 Mar 2029 | A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A | |
| Phase 3Completed | 11 Mar 2024 | A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors | |
| Phase 3Completed | 18 Jul 2024 | A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5) | |
| Phase 3Completed | 13 Nov 2024 | A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors | |
| Phase 2Completed | 6 Oct 2023 | A Research Study Investigating Mim8 in People With Haemophilia A | |
| Phase 1Completed | 13 Oct 2023 | A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and Cartridge |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026